IL111942A - Transdermal therapeutic system containing a parasympathomimetic compound and a parasympatholytic compound - Google Patents

Transdermal therapeutic system containing a parasympathomimetic compound and a parasympatholytic compound

Info

Publication number: IL111942A
Authority: IL; Israel
Prior art keywords: transdermal therapeutic; therapeutic system; parasympathomimetic; parasympatholytic; physostigmine
Prior art date: 1993-12-10

Application number

IL111942A

Other languages

English (en)

Other versions

IL111942A0 (en

Original Assignee

Lohmann Therapie Syst Lts

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-10

Filing date

1994-12-09

Publication date

1998-02-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6504684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL111942(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-12-09 Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts

1995-03-15 Publication of IL111942A0 publication Critical patent/IL111942A0/xx

1998-02-08 Publication of IL111942A publication Critical patent/IL111942A/en

Links

230000001225 therapeutic effect Effects 0.000 title claims abstract description 16
230000001499 parasympathomimetic effect Effects 0.000 title claims description 15
239000000812 cholinergic antagonist Substances 0.000 title claims description 14
230000002445 parasympatholytic effect Effects 0.000 title claims description 14
150000001875 compounds Chemical class 0.000 title description 8
239000013543 active substance Substances 0.000 claims abstract description 23
231100000572 poisoning Toxicity 0.000 claims abstract description 16
230000000607 poisoning effect Effects 0.000 claims abstract description 16
238000011321 prophylaxis Methods 0.000 claims abstract description 5
231100000331 toxic Toxicity 0.000 claims abstract description 5
230000002588 toxic effect Effects 0.000 claims abstract description 5
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
239000002581 neurotoxin Substances 0.000 claims abstract 2
231100000618 neurotoxin Toxicity 0.000 claims abstract 2
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims description 38
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims description 38
229960001697 physostigmine Drugs 0.000 claims description 38
229960002646 scopolamine Drugs 0.000 claims description 31
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 21
229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 20
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 20
RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 claims description 15
229960002290 pyridostigmine Drugs 0.000 claims description 15
239000000544 cholinesterase inhibitor Substances 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 7
238000002203 pretreatment Methods 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims 4
RXBYRTSOWREATF-UHFFFAOYSA-N 1,2,3,4-tetrahydroacridine Chemical compound C1=CC=C2C=C(CCCC3)C3=NC2=C1 RXBYRTSOWREATF-UHFFFAOYSA-N 0.000 claims 2
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 claims 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 claims 1
RRGMXBQMCUKRLH-CTNGQTDRSA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-heptylcarbamate Chemical compound C12=CC(OC(=O)NCCCCCCC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C RRGMXBQMCUKRLH-CTNGQTDRSA-N 0.000 claims 1
229960003980 galantamine Drugs 0.000 claims 1
BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 claims 1
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 claims 1
229960002362 neostigmine Drugs 0.000 claims 1
LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 claims 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 1
229930004668 tropane alkaloid Natural products 0.000 claims 1
150000003813 tropane derivatives Chemical class 0.000 claims 1
STECJAGHUSJQJN-VJQRDGCPSA-N chembl3084722 Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-VJQRDGCPSA-N 0.000 description 25
GRXKLBBBQUKJJZ-UHFFFAOYSA-N Soman Chemical compound CC(C)(C)C(C)OP(C)(F)=O GRXKLBBBQUKJJZ-UHFFFAOYSA-N 0.000 description 19
208000005374 Poisoning Diseases 0.000 description 14
230000000694 effects Effects 0.000 description 14
238000002560 therapeutic procedure Methods 0.000 description 12
230000001681 protective effect Effects 0.000 description 11
238000011282 treatment Methods 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
239000007933 dermal patch Substances 0.000 description 8
239000000243 solution Substances 0.000 description 7
239000000853 adhesive Substances 0.000 description 6
230000001070 adhesive effect Effects 0.000 description 6
229940112021 centrally acting muscle relaxants carbamic acid ester Drugs 0.000 description 6
239000010410 layer Substances 0.000 description 6
JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 6
102100033639 Acetylcholinesterase Human genes 0.000 description 5
108010022752 Acetylcholinesterase Proteins 0.000 description 5
229930003347 Atropine Natural products 0.000 description 5
241000700198 Cavia Species 0.000 description 5
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 5
229940022698 acetylcholinesterase Drugs 0.000 description 5
229960000396 atropine Drugs 0.000 description 5
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 5
150000002923 oximes Chemical class 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 4
241000282887 Suidae Species 0.000 description 4
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
102000003914 Cholinesterases Human genes 0.000 description 3
108090000322 Cholinesterases Proteins 0.000 description 3
239000004820 Pressure-sensitive adhesive Substances 0.000 description 3
HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 3
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
229960004373 acetylcholine Drugs 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
239000012790 adhesive layer Substances 0.000 description 3
229960002028 atropine sulfate Drugs 0.000 description 3
230000037396 body weight Effects 0.000 description 3
229940048961 cholinesterase Drugs 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
239000002917 insecticide Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
239000003094 microcapsule Substances 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
229960001136 obidoxime chloride Drugs 0.000 description 3
ZIFJVJZWVSPZLE-UHFFFAOYSA-N oxo-[[1-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxymethyl]pyridin-4-ylidene]methyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1COCN1C=CC(=C[NH+]=O)C=C1 ZIFJVJZWVSPZLE-UHFFFAOYSA-N 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
229920000058 polyacrylate Polymers 0.000 description 3
229920000728 polyester Polymers 0.000 description 3
238000011084 recovery Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
PJVJTCIRVMBVIA-JTQLQIEISA-N [dimethylamino(ethoxy)phosphoryl]formonitrile Chemical compound CCO[P@@](=O)(C#N)N(C)C PJVJTCIRVMBVIA-JTQLQIEISA-N 0.000 description 2
YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
230000032683 aging Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
150000004657 carbamic acid derivatives Chemical class 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
-1 diethyl-( -nitrophenyl)-thiophosphate Chemical compound 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
231100000225 lethality Toxicity 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229960004429 obidoxime Drugs 0.000 description 2
HIGRLDNHDGYWQJ-UHFFFAOYSA-P obidoxime Chemical compound C1=CC(=C[NH+]=O)C=CN1COCN1C=CC(=C[NH+]=O)C=C1 HIGRLDNHDGYWQJ-UHFFFAOYSA-P 0.000 description 2
239000000734 parasympathomimetic agent Substances 0.000 description 2
229940005542 parasympathomimetics Drugs 0.000 description 2
LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 2
229960003370 pralidoxime Drugs 0.000 description 2
JBKPUQTUERUYQE-UHFFFAOYSA-O pralidoxime Chemical compound C[N+]1=CC=CC=C1\C=N\O JBKPUQTUERUYQE-UHFFFAOYSA-O 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
239000011241 protective layer Substances 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
LACQPOBCQQPVIT-SEYKEWMNSA-N scopolamine hydrobromide trihydrate Chemical compound O.O.O.Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 LACQPOBCQQPVIT-SEYKEWMNSA-N 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000003204 tranquilizing agent Substances 0.000 description 2
230000002936 tranquilizing effect Effects 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
RVSDDUDYNOZLCG-UHFFFAOYSA-N 2-(1-methylpiperidin-4-yl)-1-phenylcyclopentane-1-carboxylic acid;hydrochloride Chemical compound Cl.C1CN(C)CCC1C1C(C=2C=CC=CC=2)(C(O)=O)CCC1 RVSDDUDYNOZLCG-UHFFFAOYSA-N 0.000 description 1
IVQOFBKHQCTVQV-UHFFFAOYSA-N 2-hydroxy-2,2-diphenylacetic acid 2-(diethylamino)ethyl ester Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 IVQOFBKHQCTVQV-UHFFFAOYSA-N 0.000 description 1
XBIUWALDKXACEA-UHFFFAOYSA-N 3-[bis(2,4-dioxopentan-3-yl)alumanyl]pentane-2,4-dione Chemical compound CC(=O)C(C(C)=O)[Al](C(C(C)=O)C(C)=O)C(C(C)=O)C(C)=O XBIUWALDKXACEA-UHFFFAOYSA-N 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229940122601 Esterase inhibitor Drugs 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
241001124569 Lycaenidae Species 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
ZJVKLBBPLUXEAC-UHFFFAOYSA-N Pipethanate hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C(=O)OCC[NH+]1CCCCC1 ZJVKLBBPLUXEAC-UHFFFAOYSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
JJIUCEJQJXNMHV-UHFFFAOYSA-N VX nerve agent Chemical compound CCOP(C)(=O)SCCN(C(C)C)C(C)C JJIUCEJQJXNMHV-UHFFFAOYSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000037374 absorbed through the skin Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000003504 ach effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000729 antidote Substances 0.000 description 1
229960001498 benactyzine Drugs 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960003120 clonazepam Drugs 0.000 description 1
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
229940042400 direct acting antivirals phosphonic acid derivative Drugs 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000002329 esterase inhibitor Substances 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
230000036540 impulse transmission Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
229960003019 loprazolam Drugs 0.000 description 1
UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
208000022084 motor paralysis Diseases 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
150000003007 phosphonic acid derivatives Chemical class 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920006267 polyester film Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000004080 punching Methods 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960004499 scopolamine hydrobromide Drugs 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
229940125725 tranquilizer Drugs 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL111942A 1993-12-10 1994-12-09 Transdermal therapeutic system containing a parasympathomimetic compound and a parasympatholytic compound IL111942A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4342174A DE4342174C1 (de)	1993-12-10	1993-12-10	Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung

Publications (2)

Publication Number	Publication Date
IL111942A0 IL111942A0 (en)	1995-03-15
IL111942A true IL111942A (en)	1998-02-08

Family

ID=6504684

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL111942A IL111942A (en)	1993-12-10	1994-12-09	Transdermal therapeutic system containing a parasympathomimetic compound and a parasympatholytic compound

Country Status (19)

Country	Link
US (1)	US5939095A (fr)
EP (1)	EP0732924B1 (fr)
JP (1)	JP3739789B2 (fr)
KR (1)	KR100397361B1 (fr)
AT (1)	ATE433339T1 (fr)
CA (1)	CA2178603C (fr)
CZ (1)	CZ291057B6 (fr)
DE (2)	DE4342174C1 (fr)
ES (1)	ES2329426T3 (fr)
FI (1)	FI122131B (fr)
HU (1)	HUT74432A (fr)
IL (1)	IL111942A (fr)
MY (1)	MY111715A (fr)
NO (1)	NO962405L (fr)
NZ (1)	NZ277492A (fr)
PL (1)	PL314914A1 (fr)
SK (1)	SK284356B6 (fr)
WO (1)	WO1995015755A1 (fr)
ZA (1)	ZA949842B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19743484C1 (de) *	1997-10-01	1999-01-28	Lohmann Therapie Syst Lts	Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
US7011843B2 (en) *	1997-10-01	2006-03-14	Lts Lohmann-Therapie Systeme Ag	Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
PT1140105E (pt) *	1998-12-24	2004-03-31	Janssen Pharmaceutica Nv	Composicao de galantamina de libertacao controlada
AU2003228796A1 (en) *	2002-05-01	2003-11-17	Eisai Co., Ltd.	Cholinesterase inhibitors to prevent injuries caused by chemicals
DE10301851A1 (de) *	2003-01-17	2004-07-29	Lts Lohmann Therapie-Systeme Ag	Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
US20050013869A1 (en) *	2003-07-18	2005-01-20	Chaw Cheng Shu	Sustained release formulation for carbamates and a method therefor
US8299062B2 (en) *	2003-09-17	2012-10-30	Franklin Volvovitz	Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
WO2005027905A1 (fr) *	2003-09-19	2005-03-31	The Secretary Of State For Defence	Compositions pharmaceutiques destinees au traitement d'un empoisonnement par un organophosphate
AU2012200612B2 (en) *	2004-09-24	2014-11-20	The Government Of The United States, As Represented By The Secretary Of The Army	Method of treating organophosphorus poisoning
US9132135B2 (en)	2004-09-24	2015-09-15	University Of Maryland, Baltimore	Method of treating organophosphorous poisoning
CA2583439C (fr) *	2004-09-24	2016-05-10	University Of Maryland, Baltimore	Methode destinee a traiter une intoxication par un organophosphore
WO2008022365A2 (fr) *	2006-08-24	2008-02-28	Sanochemia Ltd.	Agent servant à influencer les effets de composés organophosphorés et utilisation de galanthamine, de ses dérivés et analogues pour la fabrication d'un tel agent
GB0809905D0 (en) *	2008-06-02	2008-07-09	Secr Defence	A Transdermal drug delivery device
CA2828884C (fr)	2011-03-03	2021-04-27	Impel Neuropharma, Inc.	Dispositif d'administration de medicament par voie nasale
US20200163952A1 (en) *	2018-11-26	2020-05-28	Steven Hoffman	Compositions and methods for treating nerve agent exposure
KR20220098682A (ko)	2019-05-14	2022-07-12	타임, 인크.	암을 치료하기 위한 조성물 및 방법
US10905698B1 (en)	2020-05-14	2021-02-02	Tyme, Inc.	Methods of treating SARS-COV-2 infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3797494A (en) *	1969-04-01	1974-03-19	Alza Corp	Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) *	1971-08-09	1976-12-14	Alza Corporation	Medical bandage
US3742951A (en) *	1971-08-09	1973-07-03	Alza Corp	Bandage for controlled release of vasodilators
AR207805A1 (es) *	1975-02-06	1976-10-29	Alza Corp	Substrato apropiado para formar apositos para la dispensacion continua de escopolamina base por via transdermica
US4031894A (en) *	1975-12-08	1977-06-28	Alza Corporation	Bandage for transdermally administering scopolamine to prevent nausea
US4278679A (en) *	1980-05-01	1981-07-14	Chromalloy American Corporation	Combination of two or more drugs in a single dosage form wherein one of the drugs is a physostigmine compound
US4952586A (en) *	1982-08-27	1990-08-28	The Regents Of The University Of California	Edrophonium-atropine composition and therapeutic uses thereof
DE3315272C2 (de) *	1983-04-27	1986-03-27	Lohmann Gmbh & Co Kg, 5450 Neuwied	Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
IL72684A (en) *	1984-08-14	1989-02-28	Israel State	Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US5106831A (en) *	1987-08-13	1992-04-21	State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research	Pharmaceutical composition comprising a spiro oxathiolon/quinuclidine and method of treating senile dementia
US4981858A (en) *	1987-08-13	1991-01-01	State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research	Optical isomers
DE3843239C1 (fr)	1988-12-22	1990-02-22	Lohmann Therapie Syst Lts
DE3843238C1 (fr) *	1988-12-22	1990-02-22	Lohmann Therapie Syst Lts
EP0523150A4 (en) *	1990-04-06	1993-09-29	Pharmetrix Corporation	Device and method for enhanced administration of physostigmine
DE4115558A1 (de) *	1991-05-13	1992-11-19	Dresden Arzneimittel	Prophylaktisches antidot gegen phosphororganische gifte
GB9118028D0 (en) *	1991-08-21	1991-10-09	Secr Defence Brit	Improved transdrmal formulations

1993
- 1993-12-10 DE DE4342174A patent/DE4342174C1/de not_active Ceased
1994
- 1994-12-06 ES ES95903793T patent/ES2329426T3/es not_active Expired - Lifetime
- 1994-12-06 DE DE59410461T patent/DE59410461D1/de not_active Expired - Lifetime
- 1994-12-06 CZ CZ19961684A patent/CZ291057B6/cs not_active IP Right Cessation
- 1994-12-06 JP JP51596695A patent/JP3739789B2/ja not_active Expired - Fee Related
- 1994-12-06 EP EP95903793A patent/EP0732924B1/fr not_active Revoked
- 1994-12-06 HU HU9601569A patent/HUT74432A/hu unknown
- 1994-12-06 CA CA002178603A patent/CA2178603C/fr not_active Expired - Fee Related
- 1994-12-06 WO PCT/EP1994/004048 patent/WO1995015755A1/fr active IP Right Grant
- 1994-12-06 AT AT95903793T patent/ATE433339T1/de not_active IP Right Cessation
- 1994-12-06 PL PL94314914A patent/PL314914A1/xx unknown
- 1994-12-06 NZ NZ277492A patent/NZ277492A/en not_active IP Right Cessation
- 1994-12-06 US US08/656,208 patent/US5939095A/en not_active Expired - Lifetime
- 1994-12-06 SK SK739-96A patent/SK284356B6/sk not_active IP Right Cessation
- 1994-12-06 KR KR1019960702988A patent/KR100397361B1/ko not_active Expired - Fee Related
- 1994-12-08 MY MYPI94003278A patent/MY111715A/en unknown
- 1994-12-09 ZA ZA949842A patent/ZA949842B/xx unknown
- 1994-12-09 IL IL111942A patent/IL111942A/en not_active IP Right Cessation
1996
- 1996-05-27 FI FI962220A patent/FI122131B/fi not_active IP Right Cessation
- 1996-06-07 NO NO962405A patent/NO962405L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE4342174C1 (de)	1995-05-11
AU703692B2 (en)	1999-04-01
MY111715A (en)	2000-11-30
ATE433339T1 (de)	2009-06-15
CZ291057B6 (cs)	2002-12-11
KR100397361B1 (ko)	2004-03-24
FI962220L (fi)	1996-06-27
CZ168496A3 (en)	1996-11-13
AU1273395A (en)	1995-06-27
WO1995015755A1 (fr)	1995-06-15
EP0732924B1 (fr)	2009-06-10
KR960706339A (ko)	1996-12-09
PL314914A1 (en)	1996-09-30
DE59410461D1 (de)	2009-07-23
HU9601569D0 (en)	1996-08-28
FI122131B (fi)	2011-09-15
NZ277492A (en)	1998-01-26
CA2178603A1 (fr)	1995-06-15
JP3739789B2 (ja)	2006-01-25
CA2178603C (fr)	2005-08-09
SK284356B6 (sk)	2005-02-04
IL111942A0 (en)	1995-03-15
SK73996A3 (en)	1997-01-08
US5939095A (en)	1999-08-17
NO962405L (no)	1996-08-07
FI962220A0 (fi)	1996-05-27
NO962405D0 (no)	1996-06-07
ES2329426T3 (es)	2009-11-25
HUT74432A (en)	1996-12-30
EP0732924A1 (fr)	1996-09-25
ZA949842B (en)	1995-09-01
JPH09506360A (ja)	1997-06-24

Publication	Publication Date	Title
US5939095A (en)	1999-08-17	Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurotoxins in particular soman
US6562368B2 (en)	2003-05-13	Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US6602912B2 (en)	2003-08-05	Transdermal administration of phenylpropanolamine
EP0409910B1 (fr)	1995-03-01	Composite stratifie d'administration transdermique de fentanyl
US20020018803A1 (en)	2002-02-14	Transdermal administration of phenylpropanolamine
NO20151450A1 (no)	1999-10-22	Anvendelse av buprenorfin i fremstillingen av et transdermalt avleveringssystem for behandling av smerte hos en human pasient
CA1059909A (fr)	1979-08-07	Systeme therapeutique pour administrer de la scopolamine par voie transcutanee
KR20120072796A (ko)	2012-07-04	리바스티그민을 함유하는 경피흡수제제
WO2004028515A1 (fr)	2004-04-08	Timbre de type matriciel pour administration transdermique d'un analogue de la vitamine d et utilisation de ce dernier
US6114347A (en)	2000-09-05	Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors
WO2001043734A2 (fr)	2001-06-21	Administration transdermique de phenylpropanolamine
KR101399035B1 (ko)	2014-05-28	리바스티그민을 함유하는 경피흡수제제
AU2013204227B2 (en)	2017-06-15	Method of providing sustained analgesia with buprenorphine
MXPA99007798A (en)	2000-02-02	Sustained analgesia achieved with buprenorphine

Legal Events

Date	Code	Title
1998-07-15	FF	Patent granted
1999-01-26	KB	Patent renewed
2005-02-20	KB	Patent renewed
2009-06-15	KB	Patent renewed
2013-07-31	MM9K	Patent not in force due to non-payment of renewal fees